The Journal of dermatological treatment · 2025
Dupilumab for Hailey-Hailey disease.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Debeuf Marie-Eline Pauline Henriette, Vlaanderen Pip, van Geel Michel, Steijlen Peter Martin, Verstraeten Valerie Lydie Roland Marc
Аннотация
AIM: Hailey-Hailey disease is a rare autosomal dominant blistering disease predominantly affecting the skinfolds. Due to the clinical heterogeneity and lack of guidelines, diagnosis and treatment is challenging. At present, there is an increasing use of biologicals in the treatment of HHD. However, their efficacy varies.
METHODS: This case report describes the therapeutic effect of dupilumab in combination with benzathine benzylpenicillin in a 49-year-old woman with extensive therapy-resistant Hailey-Hailey disease.
RESULTS: After a follow-up period of eight months, we observed a marked improvement of the Hailey-Hailey plaques, and the patient's quality of life improved. A minor relapse occurred after 15 months, possibly due to an emotionally stressful event for the patient. No adverse events were reported.
CONCLUSION: Our case report illustrates the benefit of combining dupilumab and benzathine benzylpenicillin for extensive, therapy-resistant HHD. However, long-term complete remission remains challenging and sustained psychological support seems advised.
METHODS: This case report describes the therapeutic effect of dupilumab in combination with benzathine benzylpenicillin in a 49-year-old woman with extensive therapy-resistant Hailey-Hailey disease.
RESULTS: After a follow-up period of eight months, we observed a marked improvement of the Hailey-Hailey plaques, and the patient's quality of life improved. A minor relapse occurred after 15 months, possibly due to an emotionally stressful event for the patient. No adverse events were reported.
CONCLUSION: Our case report illustrates the benefit of combining dupilumab and benzathine benzylpenicillin for extensive, therapy-resistant HHD. However, long-term complete remission remains challenging and sustained psychological support seems advised.